IP Library Granted Patent US 10,493,053
Granted Patent B2
US 10,493,053 · App. 16/207,584 · Granted Dec 3, 2019

Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders

Inventors: Susan E. Dubé (Carlsbad, CA); Neil B. Kavey (Chappaqua, NY)
Assignees: Currax Pharmaceuticals LLC; ProCom One, Inc.
A61K31/335
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,493,053
App. No.
16/207,584
Granted
Dec 3, 2019
Kind
B2
Abstract

The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.

Claims (22)

1. A method for treating insomnia characterized by difficulties with sleep maintenance, the method comprising:

administering a dosage of doxepin or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences fragmented sleep during the final 60 minutes of said period, wherein the dosage of doxepin is between about 1 and about 6 mg, wherein the doxepin or salt thereof is a geometric isomer mixture containing about 88.3% to about 100.0% of the trans-(E) isomer or is 100% trans-(E) isomer, and wherein the dosage is administered prior to the start of the sleep period.

2. The method of claim 1 , wherein said geometric isomer mixture contains more than 90% of the trans-(E) isomer.

3. The method of claim 1 , wherein said geometric isomer mixture contains more than 95% of the trans-(E) isomer.

4. The method of claim 1 , wherein said geometric isomer mixture contains more than 98% of the trans-(E) isomer.

5. The method of claim 1 , wherein said geometric isomer mixture contains more than 99% of the trans-(E) isomer.

6. The method of claim 1 , wherein said geometric isomer mixture contains at least 99.5% or 99.9% of the trans-(E) isomer.

7. The method of claim 1 , wherein the dosage is effective to improve the insomnia while minimizing next day residual sedation.

8. The method of claim 1 , wherein the dosage is about 1 milligram.

9. The method of claim 1 , wherein the dosage is about 3 milligrams.

10. The method of claim 1 , wherein the dosage is about 6 milligrams.

11. A method for treating insomnia characterized by difficulties with sleep maintenance, the method comprising:

administering a dosage of doxepin or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences early awakenings during the final 60 minutes of said period, wherein the dosage of doxepin is between about 1 and about 6 mg, wherein the doxepin or salt thereof is a geometric isomer mixture containing about 88.3% to about 100.0% of the trans-(E) isomer or is 100% trans-(E) isomer, and wherein the dosage is administered prior to the start of the sleep period.

12. The method of claim 11 , wherein said geometric isomer mixture contains more than 90% of the trans-(E) isomer.

13. The method of claim 11 , wherein said geometric isomer mixture contains more than 95% of the trans-(E) isomer.

14. The method of claim 11 , wherein said geometric isomer mixture contains more than 98% of the trans-(E) isomer.

15. The method of claim 11 , wherein said geometric isomer mixture contains more than 99% of the trans-(E) isomer.

16. The method of claim 11 , wherein said geometric isomer mixture contains at least 99.5% or 99.9% of the trans-(E) isomer.

17. The method of claim 11 , wherein the dosage is effective to improve the insomnia while minimizing next day residual sedation.

18. The method of claim 11 , wherein the dosage is about 1 milligram.

19. The method of claim 11 , wherein the dosage is about 3 milligrams.

20. The method of claim 11 , wherein the dosage is about 6 milligrams.

Assignments (2)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: PERNIX SLEEP, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0730 →
Continuity (9)
Continuation 15357171 · Nov 21, 2016
Continuation 13692715 · Dec 3, 2012
Continuation 12535623 · Aug 4, 2009
Continuation In Part 12022788 · Jan 30, 2008
Continuation In Part 11804720 · May 18, 2007
Provisional Application 60898378 · Jan 30, 2007
Provisional Application 60801824 · May 19, 2006
Provisional Application 60833319 · Jul 25, 2006
Related Publication 20190099396A1 · Apr 4, 2019